Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Daniel Haraf and Ezra Cohen.

 
Connection Strength
 
 
 
2.535
 
  1. Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, Blair EA, Portugal L, Gooi Z, Agrawal N, Vokes EE, Haraf DJ. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22.
    View in: PubMed
    Score: 0.209
  2. Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
    View in: PubMed
    Score: 0.181
  3. Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
    View in: PubMed
    Score: 0.168
  4. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
    View in: PubMed
    Score: 0.162
  5. Maggiore RJ, Curran EK, Witt ME, Haraf DJ, Vokes EE, Cohen EE. Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. J Geriatr Oncol. 2013 Oct; 4(4):327-33.
    View in: PubMed
    Score: 0.150
  6. Golden DW, Rudra S, Witt ME, Nwizu T, Cohen EE, Blair E, Stenson KM, Vokes EE, Haraf DJ. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
    View in: PubMed
    Score: 0.144
  7. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EEW. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
    View in: PubMed
    Score: 0.128
  8. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.121
  9. Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
    View in: PubMed
    Score: 0.115
  10. Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen EE, Blair E, Vokes EE, Haraf DJ. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
    View in: PubMed
    Score: 0.108
  11. Vokes EE, Seiwert TY, Blair E, Cohen EE, Salama J, Villaflor VM, Witt M, Kovacevic M, Stenson K, Haraf D. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6067.
    View in: PubMed
    Score: 0.106
  12. Cohen EE, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, Vokes EE, Bourhis J. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84.
    View in: PubMed
    Score: 0.097
  13. Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
    View in: PubMed
    Score: 0.093
  14. Cohen EE, Haraf DJ, Stenson KM, Blair E, Brockstein BE, Mauer AM, Dekker A, Williams R, Lester E, Vokes EE. Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a Phase II Trial. J Clin Oncol. 2005 Jun; 23(16_suppl):5506.
    View in: PubMed
    Score: 0.086
  15. Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
    View in: PubMed
    Score: 0.046
  16. Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EEW, Seiwert TY, Haraf DJ, Vokes EE. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
    View in: PubMed
    Score: 0.041
  17. Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
    View in: PubMed
    Score: 0.038
  18. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFeradeā„¢ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.036
  19. Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EEW, Vokes EE, List M, Haraf DJ, Salama JK. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
    View in: PubMed
    Score: 0.035
  20. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
    View in: PubMed
    Score: 0.033
  21. Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31.
    View in: PubMed
    Score: 0.033
  22. Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
    View in: PubMed
    Score: 0.033
  23. Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen EE, Seiwert T, Vokes EE. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
    View in: PubMed
    Score: 0.032
  24. Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34.
    View in: PubMed
    Score: 0.031
  25. Choe KS, Salama JK, Stenson KM, Blair EA, Witt ME, Cohen EE, Haraf DJ, Vokes EE. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21.
    View in: PubMed
    Score: 0.031
  26. Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, Salama J, Vokes EE. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9.
    View in: PubMed
    Score: 0.030
  27. Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
    View in: PubMed
    Score: 0.029
  28. Cohn AB, Lang PO, Agarwal JP, Peng SL, Alizadeh K, Stenson KM, Haraf DJ, Cohen EE, Vokes EE, Gottlieb LJ. Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-32.
    View in: PubMed
    Score: 0.027
  29. Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94.
    View in: PubMed
    Score: 0.026
  30. Villaflor VM, Cohen EE, Haraf D, Stenson K, Blair E, Salama J, Portugal L, Williams R, Thomas A, Gomez-Abuin G, Vokes EE. Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck cancer patients. J Clin Oncol. 2008 May 20; 26(15_suppl):6030.
    View in: PubMed
    Score: 0.026
  31. Knab BR, Salama JK, Solanki A, Stenson KM, Cohen EE, Witt ME, Haraf DJ, Vokes EE. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4.
    View in: PubMed
    Score: 0.026
  32. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
    View in: PubMed
    Score: 0.026
  33. Seiwert TY, Cohen EE, Haraf DJ, Stenson K, Blair EA, Mauer A, Dekker A, Vokes EE. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44.
    View in: PubMed
    Score: 0.025
  34. Stenson KM, Huo D, Blair E, Cohen EE, Argiris A, Haraf DJ, Vokes EE. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
    View in: PubMed
    Score: 0.022
  35. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
    View in: PubMed
    Score: 0.021
  36. Hoffman PC, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.